-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
RxE2 | Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace
Introduction In the world of medical advancements, clinical trials play a crucial role in testing new drugs, treatments, and procedures to ensure their safety and efficacy. However, the traditional approach to conducting clinical trials is often time-consuming, costly, and resource-intensive. Enter RxE2, an innovative technology platform and marketplace that is revolutionizing the way clinical trials…